Accelovance Expansion Continues With Acquisition Of Radiant Development, The CRO Division Of Radiant Research
ROCKVILLE, Md., March 6, 2013 /PRNewswire-USNewswire/ -- Accelovance, Inc. announced today the acquisition of Radiant Development, the CRO division of Radiant Research. This is the latest development in an expansion strategy by the Maryland based CRO that caters to Biotech and small/mid Pharma Sponsors. Terms of the transaction were not disclosed.
Accelovance is a patient centric CRO offering innovative solutions to meet the needs of its clients. Much of the company's CRO growth has been in the vaccine, infectious disease, and oncology markets. The addition of Radiant Development broadens Accelovance's ability to provide high quality services across a range of therapeutic areas. Radiant Development has performed studies in areas including cardiovascular, men's and women's health, rheumatology, dermatology, oncology and medical device. Radiant Development also has specialized expertise in consumer health and nutrition.
"We are thrilled to have 100% of the Radiant team led by Vita Lanoce as part of our company. Core values focused on meeting our client needs, open communication and relationships built on honesty and trust are important similarities between our organizations," remarked Stephen J. Trevisan, Accelovance President and Chief Executive Officer.
Operating out of locations in Stuart, Florida, Chicago, Illinois, and Durham, North Carolina, Radiant Development has managed over 200 research studies since its inception. Additionally, the company has established strategic partnerships in Europe and Asia to offer clients global study capabilities. Radiant Development will operate as a division of Accelovance, providing full service clinical capabilities including: project management and clinical monitoring, medical, safety and pharmacovigilance, regulatory consulting, medical writing, data management and statistical services."With a shared vision of an innovative approach to execution, exceptional customer service, and focus on providing value to our clients, Radiant Development is delighted to join forces with Accelovance to offer expanded leading edge service solutions to our clients," said Vita Lanoce, Senior Vice President of Development. Current customers, employees and stake holders of Radiant Development should expect the continued high level of quality, service and performance they are accustomed to receiving. This includes an ongoing, preferred provider relationship with the Radiant Research and Clinical Research Advantage site network.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts